Rx License-Rx

TAB-1316

Transformation-Associated Recombination (TAR) Cloning

Transformation-Associated Recombination (TAR) cloning in yeast is a unique method for selective isolation of large chromosomal fragments or entire genes from complex genomes without the time-consuming step of library construction. 1 The technique involves homologous recombination during yeast spheroplast transformation between genomic DNA and a TAR vector that has short (approximately 60bp) 5’ and 3’ gene targeting sequences (hooks). Further, because up to 15% sequence divergence does not prevent recombination in yeast, TAR cloning is highly efficient for isolation of gene homologs and synthenic regions. Using this technology, chromosomal regions up to 250kb can be rescued in yeast as circular YACs within 3-5 working days. . NIH researchers Drs. Larionov, Kouprina and Resnick have championed the use of this technology and TAR cloning has been used to efficiently isolate haplotypes, gene families 4 as well as genomic regions which are...

Intelligence Memo

Owner: National Institutes of Health

Core category: Therapeutics

Therapeutic area: Platform Technology

Indication:

Modality: Cell/Gene Therapy

Focus tags: Needs review

Technology tags: Cell/Gene Therapy, Drug Delivery, Diagnostic / Biomarker

Mechanism:

Development stage: Preclinical

Patent status: Expired

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Platform Technology. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be preclinical and is associated with National Institutes of Health. The practical first use case is a pharma trial-enrichment use case before broad diagnostic commercialization. Public description: Transformation-Associated Recombination (TAR) cloning in yeast is a unique method for selective isolation of large chromosomal fragments or entire genes from complex genomes without the time-consuming step of library construction. 1 The.

What is exciting

Already past pure discovery: Preclinical validation gives a buyer something concrete to reproduce, optimize, or package into an IND-enabling plan.

Can sell into pharma before reimbursement: A biomarker or AI tool can create value as trial enrichment, patient stratification, or translational support before becoming a regulated diagnostic.

Delivery can refresh known biology: A better route, depot, local exposure profile, or targeted formulation can create new IP and reduce systemic risk around existing mechanisms.

Hot modality with strategic appetite: Cell and gene therapy buyers care when there is a crisp antigen, genetic subgroup, potency assay, or manufacturing shortcut.

Negatives / diligence concerns

Translation still unproven: Animal or lab data may not predict human performance; tox, PK/PD, CMC, and indication selection still need diligence.

First indication is not obvious: A broad use case can waste capital. The license needs one narrow patient segment or buyer problem before development starts.

Validation can be harder than the demo: Models and biomarkers need locked datasets, external validation, clinical utility, data rights, and a regulatory/reimbursement plan.

Manufacturing can dominate the budget: Potency assays, vector or cell process reproducibility, release testing, and COGS can become bigger risks than the biology.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp specialty therapeutics wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets Roche Diagnostics — Companion diagnostic and translational biomarker fit. Thermo Fisher — Research-tool commercialization and pharma services channels. Illumina / Tempus — Data, sequencing, and clinical decision-support adjacency.

Development Strategy to Increase PoS

First indication: a pharma trial-enrichment use case before broad diagnostic commercialization

Study design: Retrospective locked-dataset validation followed by one prospective pharma enrichment pilot.

Key experiments Validate the AI-optimized pivot: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed with repositioning: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero

Best next experiment: Run the smallest independent study that validates: Use a centralized CDMO, lock the release assay early, and design the first trial around tumor-antigen evidence rather than broad basket ambition.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.